reports
Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Co...
Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13, 2025, at 9:45 a.m. PT / 12:45 p.m. ET. A live webcast of this presentation can be accessed by visi...
- Jonathan Moreland
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
CULP CULP INC.
NSC NORFOLK SOUTHERN CORPORATION
PMD PSYCHEMEDICS CORP.
DMLP DORCHESTER MINERALS L.P.
BBDC BARINGS BDC INC.
DBI DESIGNER BRANDS INC. CLASS A
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
RZLT REZOLUTE
CTGO INC.
NOTV CONTANGO ORE INC.
TRIN INOTIV
IBRX INC.
GRNT TRINITY CAPITAL INC
AVDL IMMUNITYBIO INC
MIO GRANITE RIDGE RESOURCES INC
AVADEL PHARMACEUTICALS PUBLIC LIMITED COMPANY
PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
Wave Life Sciences to Present at Upcoming Investor Conferences
Wave Life Sciences to Present at Upcoming Investor Conferences CAMBRIDGE, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences in December. 7ᵗʰ Annual Evercore HealthCONx ConferenceDate: Tuesday, December 3, 2024Analyst-led fireside chat: 3:00 p.m. ET Citi 2024 Global Healthcare Conference D...
- Jonathan Moreland
MCHX MARCHEX INC. CL B
I3N CHART INDUSTRIES INC.
AGCO AGCO CORPORATION
CMCO COLUMBUS MCKINNON CORPORATION
DMLP DORCHESTER MINERALS L.P.
BBDC BARINGS BDC INC.
SURG SURGE HOLDINGS
PFBX INC.
SES PEOPLES FINANCIAL CORP. (MISSISSIPPI)
WPC SES AI CORPORATION
W. P. CAREY AND CO. LLC
- Jonathan Moreland
SEDG SOLAREDGE TECHNOLOGIES INC.
SATS ECHOSTAR CORPORATION CLASS A
PBF PBF ENERGY INC. CLASS A
OPK OPKO HEALTH INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
MCHX MARCHEX INC. CL B
KVHI KVH INDUSTRIES INC.
JRVR JAMES RIVER GROUP HOLDINGS LTD
HSII HEIDRICK & STRUGGLES INTERNATIONAL INC.
HASI
I3N HANNON ARMSTRONG SUSTAINABLE INFRASTRUCTURE CAPITAL INC.
GDOT CHART INDUSTRIES INC.
EXAS GREEN DOT CORPORATION CLASS A
CROX EXACT SCIENCES CORPORATION
CNC CROCS INC.
AGCO CENTENE CORPORATION
AVNW AGCO CORPORATION
ENPH AVIAT NETWORKS
HTLD ENPHASE ENERGY INC.
ZOM HEARTLAND EXPRESS INC.
DMLP ZOMEDICA PHARMACEUTICALS CORP
MAV DORCHESTER MINERALS L.P.
HLNE PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
SNBR HAMILTON LANE INCORPORATED CLASS A
MHI SLEEP NUMBER CORPORATION
GNL PIONEER MUNICIPAL HIGH INCOME TRUST
BBDC GALEY & LORD INC.
CLDX BARINGS BDC INC.
ENX CELLDEX THERAPEUTICS INC.
ADV EATON VANCE NEW YORK MUNICIPAL BOND FUND
HPK ADVANTAGE SOLUTIONS INC (A)
MRVI HIGHPEAK ENERGY INC (A)
OPCH MARAVAI LIFESCIENCES HOLDINGS
MODV OPTION CARE HEALTH INC
DCOM MODIVCARE INC
UAN DIME COMMUNITY BANCSHARES
PFBX INC.
OSCR CVR PARTNERS LP
BGS PEOPLES FINANCIAL CORP. (MISSISSIPPI)
WBD OSCAR HEALTH
TCBX B&G FOODS
BIGZ INC.
RXO_w WARNER BROS. DISCOVERY INC.
VANI THIRD COAST BANCSHARES INC
KLG_w BLACKROCK INNOVATION AND GROWTH TST
DBD RXO INC
MIO VIVANI MEDICAL INC
WPC WK KELLOGG CO
EVM DIEBOLD NIXDORF INCORPORATED
PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
W. P. CAREY AND CO. LLC
EATON VANCE INSD CALIF MUN BD FD
Wave Life Sciences Reports Third Quarter 2024 Financial Results and Pr...
Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update Achieved first-ever RNA editing in humans in RestorAATion-2 trial of WVE-006 (GalNAc-AIMer) in alpha-1 antitrypsin deficiency and announced three wholly owned GalNAc-AIMer preclinical programs that offer first-in-class approaches to address unmet needs in cardiometabolic diseases WVE-007 (INHBE GalNAc-siRNA) clinical trial on track for 1Q 2025; preclinical data demonstrates opportunities for monotherapy, for synergistic use with GLP-1s, and for maintenance to avoid rebound weight gain following...
Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for ...
Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024 CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, November 12, 2024, to review the company’s third quarter 2024 financial results and provide business updates. The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of ...
Wave Life Sciences Highlights Growing Pipeline at Research Day, includ...
Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs WVE-007 (INHBE GalNAc-siRNA for obesity) is on track to initiate a clinical trial in 1Q 2025; new preclinical data for WVE-007 demonstrate opportunities for monotherapy, for synergistic use with GLP-1s, and for maintenance to avoid rebound weight gain following cessation of GLP-1s Recent proof-of-mechanism data for WVE-006 unlocked Wave’s best-in-class RNA editing capabilities; three new wholly owned RNA editing programs targeting PNPLA3, LDLR and APOB ar...
PetIQ, Inc. Announces Successful Completion of Acquisition by Bansk Gr...
PetIQ, Inc. Announces Successful Completion of Acquisition by Bansk Group EAGLE, Idaho and NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication, health and wellness company, today announced the successful completion of its acquisition by Bansk Group (“Bansk”), a consumer-focused private investment firm dedicated to building distinctive consumer brands, in an all-cash transaction valued at approximately $1.5 billion. PetIQ stockholders will receive $31.00 in cash per PetIQ share in accordance with the terms of the tran...
PetIQ, Inc. Announces Results of Special Meeting of Stockholders
PetIQ, Inc. Announces Results of Special Meeting of Stockholders Reports Merger Agreement with Bansk Group Approved by Stockholders and Anticipates a Closing Date of October 25, 2024 EAGLE, Idaho, Oct. 22, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication, health and wellness company, announced today that at its virtual Special Meeting of Stockholders approximately 80% of its outstanding shares of common stock voted to approve the adoption of the definitive merger agreement (the “Agreement”) pursuant to which Bansk Group will acquir...
Wave Life Sciences Ltd: 2 directors
Two Directors at Wave Life Sciences Ltd sold/sold after exercising options 299,310 shares at between 13.671USD and 15.000USD. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades b...
Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Hum...
Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency Achieved proof-of-mechanism for Wave’s RNA editing platform; restoring levels of wild-type (edited) M-AAT that are consistent with the heterozygous “MZ” genotype with low risk of AATD lung and liver disease A single subcutaneous dose of WVE-006 in the first two patients with homozygous “ZZ” AATD resulted in mean plasma total AAT levels of ~11 micromolar, with mean wild-type M-AAT representing more than 60% of total AAT; durable editing wi...
Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesda...
Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024 Event will highlight WVE-006 for AATD and Wave’s rapidly advancing, wholly owned pipeline of RNA medicines, including introducing new RNA editing programs and new preclinical data for WVE-007 INHBE program for obesity CAMBRIDGE, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced it will host a virtual Research Day on Wednesday, Octo...
Wave Life Sciences Announces Closing of Upsized Public Offering of Ord...
Wave Life Sciences Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today that it closed its previously announced underwritten public offering, and that the underwriters exercised in full their option to purchase an additional 3,750,000 of its ordinary share...
Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines ...
Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Chardan 8th Annual Genetic Medicines Conference in New York City on Tuesday, October 1, 2024, at 1:00 p.m. ET. A live webcast of this presentation ...
Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordi...
Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants CAMBRIDGE, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today the pricing of its previously announced underwritten public offering of 23,125,001 of its ordinary shares at a price to the public of $8.00 per ordinary share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 1,875...
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shar...
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants CAMBRIDGE, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today that it has commenced an underwritten public offering of $175 million in aggregate of its ordinary shares, and, to certain investors that so choose in lieu of ordinary shares, pre-funded warrants to purchase ordinary shares. In connection with the offering, Wave int...
Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Cli...
Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping Mean muscle content-adjusted dystrophin expression of 9.0% and unadjusted dystrophin of 5.5%, with high consistency across participants, in a prespecified analysis; dystrophin was comprised of two isoforms consistent with Becker muscular dystrophy patients who display milder disease Data demonstrated meaningful improvement in serum biomarkers for muscle health, with localization of WVE-N531 in myogenic stem cells and reg...
Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for...
Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy Designation highlights significant unmet needs in DMD; dystrophin data from potentially registrational FORWARD-53 trial of WVE-N531 are on track for 3Q 2024 In previous Part A trial, WVE-N531 achieved industry-leading exon skipping of 53% and muscle tissue concentrations that were approximately 20-30 times higher than those reported by exon skipping technologies leveraging muscle delivery conjugates CAMBRIDGE, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Wave Li...
Wave Life Sciences Reports Second Quarter 2024 Financial Results and P...
Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update Successful clinical translation of Wave’s RNA medicines platform in HD patients with WVE-003 provides further validation of Wave’s proprietary platform with PN and stereochemistry; opt-in package for WVE-003 submitted to partner Takeda and engagement with regulators initiated to discuss potential path to accelerated approval Dystrophin data on track for 3Q 2024 from potentially registrational FORWARD-53 trial of WVE-N531, which has previously demonstrated industry-leading exon skipping of 53%; p...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.